Genetic microevolution of clinical Candida auris with reduced Amphotericin B sensitivity in China.

ABSTRACT: The global rate of Amphotericin B (AmB) resistance in Candida auris has surpassed 12%. However, there is limited data on available clinical treatments and microevolutionary analyses concerning reduced AmB sensitivity. In this study, we collected 18 C. auris isolates from five patients between 2019 and 2022. We employed clinical data mining, genomic, and transcriptomic analyses to identify genetic evolutionary features linked to reduced AmB sensitivity in these isolates during clinical treatment. We identified six isolates with a minimum inhibitory concentration (MIC) of AmB below 0.5 µg/mL (AmB^0.5) and 12 isolates with an AmB-MIC of 1 µg/mL (AmB¹) or ≥ 2 µg/mL (AmB²). All five patients received 24-hour AmB (5 mg/L) bladder irrigation treatment

SUBMITTER: Tian S 

PROVIDER: S-EPMC11385638 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature